Bristol Myers Squibb Receives FDA Approval for Sotyktu in Psoriatic Arthritis

Bristol Myers Squibb today announced that the FDA has approved Sotyktu (deucravacitinib) for the treatment of adults with active psoriatic arthritis. In the Phase 3 POETYK PSA-1 and PSA-2 trials, Sotyktu demonstrated statistically significant improvements in ACR20 response rates compared to placebo. This approval expands Sotyktu's indications beyond plaque psoriasis, making it the first TYK2 inhibitor approved for psoriatic arthritis. Sotyktu is a selective, allosteric TYK2 inhibitor that modulates IL-12, IL-23, and type I interferon signaling.